This clinical trial is focused on studying the treatment of Non-Small Cell Lung Cancer (NSCLC), specifically in patients with stages II and III of the disease. The study involves the use of a medication called Durvalumab, also known by its code name MEDI4736. Durvalumab is an immunotherapy drug that helps the immune system fight cancer. The trial will also involve various chemotherapy drugs, including Cisplatin, Carboplatin, Gemcitabine, Gemcitabine Hydrochloride, Pemetrexed, Pemetrexed Disodium, Paclitaxel, Infliximab, and Mycophenolate Mofetil. These medications will be administered to patients before and after surgery to remove the cancer.

The purpose of the study is to compare the effectiveness of Durvalumab combined with chemotherapy to a placebo combined with chemotherapy. The study will assess how well the treatment works in terms of event-free survival (EFS), which means the length of time patients remain free from certain complications or events related to cancer. It will also look at the pathological complete response (pCR), which refers to the absence of cancer cells in tissue samples after treatment. Patients will receive the treatment intravenously, meaning it will be given through a vein, and the study will follow their progress over time.

Participants in the study will undergo treatment both before and after their cancer surgery. The study aims to provide valuable information on whether adding Durvalumab to the standard chemotherapy regimen can improve outcomes for patients with operable NSCLC. The trial is expected to continue until 2028, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatment.